- Home
- RDIB vs OCGN Comparison
RDIB vs OCGN Comparison
Compare RDIB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- OCGN
- Stock Information
- Founded
- RDIB 1937
- OCGN 2013
- Country
- RDIB United States
- OCGN United States
- Employees
- RDIB N/A
- OCGN N/A
- Industry
- RDIB Movies/Entertainment
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDIB Consumer Discretionary
- OCGN Health Care
- Exchange
- RDIB Nasdaq
- OCGN Nasdaq
- Market Cap
- RDIB 279.6M
- OCGN 321.7M
- IPO Year
- RDIB N/A
- OCGN N/A
- Fundamental
- Price
- RDIB $11.55
- OCGN $1.16
- Analyst Decision
- RDIB
- OCGN Strong Buy
- Analyst Count
- RDIB 0
- OCGN 3
- Target Price
- RDIB N/A
- OCGN $6.00
- AVG Volume (30 Days)
- RDIB 6.3K
- OCGN 2.3M
- Earning Date
- RDIB 11-13-2025
- OCGN 11-07-2025
- Dividend Yield
- RDIB N/A
- OCGN N/A
- EPS Growth
- RDIB N/A
- OCGN N/A
- EPS
- RDIB N/A
- OCGN N/A
- Revenue
- RDIB $219,213,000.00
- OCGN $4,754,000.00
- Revenue This Year
- RDIB $5.21
- OCGN N/A
- Revenue Next Year
- RDIB $11.45
- OCGN N/A
- P/E Ratio
- RDIB N/A
- OCGN N/A
- Revenue Growth
- RDIB 7.59
- OCGN N/A
- 52 Week Low
- RDIB $5.78
- OCGN $0.52
- 52 Week High
- RDIB $14.95
- OCGN $1.29
- Technical
- Relative Strength Index (RSI)
- RDIB 46.80
- OCGN 66.66
- Support Level
- RDIB $9.99
- OCGN $1.00
- Resistance Level
- RDIB $12.91
- OCGN $1.25
- Average True Range (ATR)
- RDIB 0.77
- OCGN 0.04
- MACD
- RDIB -0.17
- OCGN 0.01
- Stochastic Oscillator
- RDIB 42.62
- OCGN 65.31
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").